Oncoshot

Meet the startups behind Singapore's emerging innovations. Join us at the Singapore Innovation & Enterprise Showcase taking place on 15 January 2025, at the San Francisco Marriott Marquis during the J.P. Morgan Annual Healthcare Conference week. This event will showcase Singapore’s most innovative #startups and offer a unique opportunity for innovators, entrepreneurs, and investors to connect, collaborate, and exchange ideas. Plus, join our panel discussion on Singapore's biomedical ecosystem and opportunities in Asia-Pacific, with Amy Schulman of Polaris Partners, Ansbert Gadicke of MPM BioImpact, Alessandro Falcone of JLABS Singapore, Hugo Saavedra of KYAN Technologies, and Irene Cheong of A*STAR - Agency for Science, Technology and Research. Register now: https://lnkd.in/gUZCM_Th Learn more about presenting startups: https://lnkd.in/gZbzHdm2 Ananda Immunotherapies | AUM Biosciences | Avecris | Axcynsis Therapeutics | BioSyngen | BluMaiden Biosciences | ImmunoScape | Nuevocor | PairX Bio | Paratus Sciences | Tikva Allocell Pte Ltd | VerImmune | Auristone Pte Ltd | BioCheetah Pte Ltd | KYAN Technologies | Lucence | Qritive | Nousq Pte Ltd | Vivo Surgical | Aevice Health | Biorithm | Mesh Bio | Oncoshot | CoNEX Healthcare | Respiree

AI in Healthcare: Unlocking the Future of SaaS Some of you might have caught the viral video about Microsoft’s CEO Satya Nadella voicing, “SaaS is dead,”. For healthcare, however, it’s not about the end of SaaS but its evolution. Cloud-delivered software is being transformed by AI, offering exciting opportunities to improve clinical care, research, and hospital operations. Why Healthcare Hesitates with SaaS Healthcare systems, especially public institutions and the vast majority in APAC and EU, have traditionally been cautious about adopting SaaS. Concerns around data privacy, security, and compliance with regulations like GDPR and HIPAA have slowed adoption. However, healthcare-compliant cloud infrastructure has matured over the last several years. These systems can now meet the industry’s strict standards while enabling secure, scalable innovation. AI and SaaS: A Smarter Partnership AI doesn’t replace SaaS; it supercharges it. Instead of static dashboards or rigid workflows, AI makes systems more dynamic and useful. For example in Oncoshot’s use cases of Clinical trials and RWE: ✅Clinicians can ask AI to find eligible patients for trials or analyze real-world survival data in a natural language query as opposed to getting their IT team to get those insight. ✅Administrators can uncover operational inefficiencies and differences prescribing behavior and outcomes. While challenges like cost and compute resources remain depending on the applications, AI-driven SaaS promises smarter, adaptive systems that respond to real-world needs. The Logic Layer: Making AI Reliable The foundation of this transformation is the logic layer. This ensures data isn’t just stored but organized and enriched for meaningful use. It plays a critical role by: 👍Validating AI results to avoid errors or hallucinations. 👍Structuring raw data into actionable insights. At Oncoshot, tools like OS-EXTA, OS-ENRA, and OS-MAIA help build this layer within hospital-controlled cloud environments. These tools structure clinical and operational data, creating a reliable foundation for AI to thrive responsibly. The Future of AI in Healthcare With the convergence of AI and healthcare-compliant infrastructure, we are entering an era where technology evolves from being a tool to becoming a trusted partner. From improving patient care to driving research, the potential is transformative. Exciting times for healthcare systems and the life sciences industry! Oncoshot Oncoshot India Ruslan Enikeev Chee Yong Chua Dr. Nilesh Atre Andrew Wilson David Chia Thanuja Naidu Shabbir Syed Abdul

Next week, I’ll be in San Francisco during one of healthcare’s most influential gatherings, the JP Morgan Healthcare Conference #JPM2025. This year, AI in Healthcare and Life Sciences will continue to take center stage, and Oncoshot is proud to be part of the conversation. As Asia's leading health insights exchange platform, we're tackling the most complex data challenges in oncology through the power of advanced technologies. Our solutions leverage data extraction automation and oncology fine-tuned LLMs to empower cancer centres with streamlined data management, foster stronger collaborations between healthcare systems and industry, and connect patients with cutting-edge clinical trials and research. If you’re interested in exploring collaborations, let’s connect in person in San Francisco next week! #JPM2025 #OncologyResearch #AIinHealthcare #ClinicalInnovation #FutureOfHealthcare Ruslan Enikeev Chee Yong Chua Dr. Nilesh Atre Andrew Wilson Yigit Yucel Oncoshot Oncoshot India Enterprise Singapore JLABS Nicole A. Pang Xue Bin Derek Neo Alessandro Falcone, MD Ronne Yeo Kenneth Goh Anvesh Ramineni Cheryl Teo

2024 - Drenched, tired and a tad crazy. But we're all still smiling :) As 2024 comes to a close, I’m reflecting on a year of resilience and progress for Oncoshot. Despite the challenging climate for startups, we’ve made significant financial and operational strides. More than ever, I'm confident in Oncoshot’s vision and impact as we lay the groundwork for a future where oncology research is efficient, cost-effective, and near-realtime health data sharing between healthcare systems and innovators can be a reality. Some highlights from this year: 1. Empowering Hospitals with Better Data This year, we strengthened our value proposition for hospitals with technologies for automated data extraction and restructuring of clinical data. By addressing long-standing barriers to entry (ie manpower to restructure data), we’ve made it easier for hospitals to manage research data effectively. Starting in APAC, this approach is now gaining traction with hospital partners in US, UK, and EU, underscoring the global demand for better systems. The coming 6 mths will be focused on executing data pipelines for 3 large health system partners globally. 2. Strengthening Industry Collaboration We proudly launched Singapore’s first industry-supported tumor registry, proving how public-private partnerships can unlock new opportunities and reshape oncology research. I'm excited about how we are collectively building new models of #RWE consumption with more real-time aggregate insights sharing. While we look to bring more industry partners to participate in the ongoing projects in Singapore, we are also in the midst of strategising new projects with the same innovative industry partners across other health systems outside SG. 3. Innovating for the Future, Today. A major milestone this year was the launch of RecommendTx, our oncology-tuned LLM solution that matches cancer patients with clinical trials. In the coming year, we will be doubling down on our fine-tuned LLM model to expand its capabilities across RWE - expanding the power of our LLM and to deploy this LLM locally in a cost efficient model. We are delighted to partner with the likes of Amazon Web Services (AWS) as a public sector partner to make our LLM available in a federated and affordable manner for our hospitals. As I reflect, I am deeply grateful to everyone who has been part of this journey. Your support has been critical in empowering our vision to transform cancer data and research. Here’s to 2025—a year of more innovation, collaboration, and breakthroughs. Wishing you all a Happy New Year! 🎉 #Innovation #Oncology #Collaboration #NewYear2025 #Healthcare   Oncoshot Oncoshot India Ruslan Enikeev Chee Yong Chua Dr. Nilesh Atre Andrew Wilson Thanuja Naidu Yigit Yucel

Harnessing AI to Transform Clinical Development It was great to have participated in the "Harnessing AI and Digital Technology to Accelerate Clinical Development" panel discussion at #JLABS Singapore two weeks ago. James Gallagher, Head of Early Innovation at Johnson & Johnson, provided a clear and compelling overview of how AI is transforming clinical trials—from smarter design to enhanced patient recruitment. A/Prof Danny Soon, CEO of Consortium for Clinical Research and Innovation, Singapore (CRIS) and Singapore Clinical Research Institute (SCRI), shared public sector insights on drivers of progress in Singapore’s clinical research ecosystem. Sharon Chen, CEO of AlphaLife Sciences, shared examples on how #GenAI is revolutionizing clinical workflows for biopharma, highlighting the rapid innovation in this space to improve efficiency.. I had the chance to discuss how AI can enable trusted and efficient extraction and management of healthcare data to support clinical development. There’s still much to be done on the data front—ensuring accessibility, quality, and readiness to truly unlock AI’s full potential. That said, we’re at a remarkable point in time, with immense opportunities to collaborate and advance clinical development like never before. A big thank you to Alessandro Falcone, MD, Head JLABS Singapore, and Sharon Chan, VP JLABS APAC, for organizing such a dynamic and impactful event. Bringing together public and private stakeholders, pharma, and startups is exactly what’s needed to drive innovation and deliver better outcomes for patients. Excited for what’s next! #AIinHealthcare #ClinicalInnovation Oncoshot #JLABSSingapore #Collaboration #DigitalHealth #ClinicalTrials #PharmaInnovation Kenneth Goh Ran Tao Sravanthy Manesh Ruslan Enikeev Chee Yong Chua Yigit Yucel Germaine L Megan Chu Mei Kan Dr. Nilesh Atre Andrew Wilson Shabbir Syed Abdul Zubin Daruwalla Bernard Ng Simon Hopkins

A recent article in The Straits Times has ignited crucial conversations about #Singapore's cancer care strategies, spotlighting the urgent need to address our rapidly evolving healthcare ecosystem. While the outcomes reported in the particular industry-sponsored white paper may have been misrepresented, the debate raises critical questions about our approach to cancer care and population health as a whole. Over the past three years, Singapore's national press has covered a range of pressing topics, from the soaring costs of cancer treatment to the challenges patients face in accessing life-saving therapies amidst a backdrop of rapidly advancing technologies and innovations. These discussions present a unique opportunity to ask deeper questions about the role of data in transforming our legacy reactive approaches into a more proactive and dynamic system. #cancer #pophealth #RWE Ruslan Enikeev Chee Yong Chua Zubin Daruwalla Devanathan Raghunathan PhD MBA Clive Tan

How do we solve oncology’s toughest data challenges? Last week, we brought together some of the top oncology experts to tackle this question head-on. Here's what we uncovered: 𝗗𝗮𝘁𝗮 𝗜𝘀𝘀𝘂𝗲𝘀 𝗔𝗿𝗲 𝗦𝗹𝗼𝘄𝗶𝗻𝗴 𝗗𝗼𝘄𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 Siloed platforms and manual data extraction require significant labor, creating inefficiencies that delay clinical trials and real-world evidence studies. In fact, more than 80% of clinical trials fail to enroll on time, resulting in study extensions or the addition of new study sites. (1) 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗱𝗮𝘁𝗮 𝗶𝘀𝗻’𝘁 𝘀𝘁𝗮𝗻𝗱𝗮𝗿𝗱𝗶𝘇𝗲𝗱 𝗮𝗰𝗿𝗼𝘀𝘀 𝘀𝘆𝘀𝘁𝗲𝗺𝘀 A staggering 97% of healthcare data goes unused because it’s unstructured. Inconsistent and incomplete data limit the progress in research. (2) 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗱𝗮𝘁𝗮 𝗯𝗲𝗰𝗼𝗺𝗲𝘀 𝗼𝘂𝘁𝗱𝗮𝘁𝗲𝗱 𝗾𝘂𝗶𝗰𝗸𝗹𝘆 Patient records often miss critical updates, such as new treatments or diagnoses. This lack of up-to-date information leads to unreliable insights. When these challenges persist, they cause delays, wasted resources, and diminished trust in data accuracy—roadblocks that oncology research can’t afford. 𝗛𝗼𝘄 𝗧𝗼 𝗢𝘃𝗲𝗿𝗰𝗼𝗺𝗲 𝗧𝗵𝗲𝘀𝗲 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀? The good news is that today’s technology can help solve these problems in a 𝘀𝗲𝗰𝘂𝗿𝗲, 𝗮𝗰𝗰𝘂𝗿𝗮𝘁𝗲, 𝗮𝗻𝗱 𝘀𝗰𝗮𝗹𝗮𝗯𝗹𝗲 way. At Oncoshot, we’ve developed solutions that empower hospitals and researchers to overcome these challenges head-on. They work seamlessly within existing healthcare systems, saving time, improving accuracy, and accelerating oncology research. A big 𝘁𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 to everyone who joined our discussions last week and shared their valuable insights—your expertise is helping drive meaningful solutions in oncology research. Join the conversation! Reach out to us on support@oncoshot.com to learn more. (1) "Recruitment and retention of participants in clinical studies: Critical issues and challenges", Mira Desai, 2020 (2) "The Current State of AI in Healthcare and Where It's Going in 2023", HealthTech Magazine, 2023

In an era where clinical trials require more efficient and streamlined processes to reduce complexity and enhance accuracy, AI is well-positioned to make a significant impact. 🤝 A/Prof Danny Soon, CEO CRIS and Executive Director of Singapore Clinical Research Institute (SCRI), together with esteemed panelists Dr Huren Sivaraj, CEO and Co-Founder, Oncoshot and Sharon Chen, CEO and Co-Founder, AlphaLife Sciences, spoke on the topic "Harnessing AI and digital technology to accelerate clinical development" at a panel organised by JLABS Singapore on 5 December 2024. In his introduction, A/Prof Danny Soon referenced the example of Nobel Prize winner for Chemistry, Demis Hassabis, a former child chess prodigy who founded AI company DeepMind which developed AlphaZero, a learning algorithm that revolutionised computer chess. In the same vein, he highlighted the immense potential for AI to speed up operational aspects of #clinicaltrials and enhance the use of digital biomarkers in healthcare. The panellists highlighted the power of AI in enhancing data management in #clinicalresearch, and emphasised the need for robust data governance, security features, and regulations for AI to bring valuable impact for good. They also agreed on how closer collaboration from both the life sciences industry and healthcare providers can further the possibilities of novel use-applications of AI in future. The session was opened by Dr Alessandro Falcone, MD, Head, JLABS Singapore, Johnson & Johnson, and the panel was moderated by James Gallagher, Head of Early Innovation – Innovative Health, Global Development, Johnson & Johnson Innovative Medicine. At this final panel for the year, panellists shared their inspiring take on “the dream AI product’ that will have the most significant impact on the future of #clinicaldevelopment in future: ⚛️ Dr Huren Sivaraj shared the potential for AI to develop up-to-date use-cases to enhance insights for healthcare professionals amid an ever-evolving landscape of clinical trials, to better serve patients and match them to clinical trials that are suited for them. ⚛️ Ms Sharon Chen shared her hopes for the potential for next #GenAI to introduce automation to generate research reports and improve efficiencies, as well as for AI capabilities to comb through troves of publications and scour for unique insights that will highlight learnings from past examples to apply better strategies and study design to improve overall success rate of clinical studies in future. ⚛️ A/Prof Danny Soon shared how AI capabilities can support in-depth data-driven analysis of research proposals and portfolio submissions to enable more strategic approaches to support evaluation process and decision-making in the long run.

“What excites you most about the advancements in AI?” At the "Harnessing AI and Digital Technology to Accelerate Clinical Development" panel by JLABS Singapore, Dr. Huren Sivaraj addressed this question and more, sharing how AI is reshaping healthcare. Through Oncoshot, we’re leveraging AI to bridge critical gaps in the healthcare ecosystem, provide efficient and timely access to structured data, enhance patient matching for clinical trials, and generate actionable insights for all partners. These innovations are accelerating meaningful progress in oncology research—and we’re just getting started! A big thank you to Danny Soon and Sharon Chen for their inspiring insights, and to JLABS, Alessandro Falcone, MD, and James Gallagher for hosting such an impactful and thought-provoking final event of the year. Here’s to pushing the boundaries of innovation in 2025! #AIinHealthcare #JLABSSG  #OncologyInnovation #ClinicalTrials #HealthcareTransformation #OncologyResearch #ClinicalTrialInnovation #DigitalHealth #PrecisionOncology #HealthTech #AsiaHealthcare #CancerResearch

We're excited to share that our CEO, Dr. Huren Sivaraj, will be part of an expert panel at JLABS' event on December 5th in Singapore. Join us for a thought-provoking panel discussion on how #AI and digital technologies are revolutionizing life sciences—empowering faster patient recruitment, streamlining clinical trials, and addressing the most pressing challenges in clinical research today. Dr. Huren will be joined by distinguished leaders: - Danny Soon, Chief Executive Officer at the Consortium for Clinical Research and Innovation Singapore (CRIS) - Sharon Chen, CEO of AlphaLife Sciences Moderated by James Gallagher, Head of Early Innovation at Johnson & Johnson Innovative Medicine, this session promises insights into emerging innovations in clinical development. If you're attending the #ESMO Asia Congress or in Singapore, don't miss this opportunity to hear from industry leaders. 📅 Mark your calendar and RSVP here: https://lnkd.in/eFUJB2kn #HealthcareInnovation #ClinicalTrials #DigitalHealth #Oncology #OncologyResearch #AI Huren Sivaraj Ruslan Enikeev Chee Yong Chua Megan Chu Mei Kan Germaine L Thanuja Naidu Shabbir Syed Abdul Andrew Wilson Dr. Nilesh Atre Yigit Yucel Ruhi Reddy Arpita Chavan Tam C. Nguyen David Chia Oncoshot India